Results 121 to 130 of about 99,136 (277)

Optical genome mapping detects cryptic high‐risk and targetable abnormalities in adult AML

open access: yesBritish Journal of Haematology, EarlyView.
Summary Acute myeloid leukaemia (AML) risk stratification relies on cytogenetic and molecular abnormalities defined by European LeukemiaNet (ELN) 2022. Conventional cytogenetic techniques, including chromosomal banding analysis (CBA) and fluorescence in situ hybridization, have limited resolution and may miss cryptic events. Optical genome mapping (OGM)
Audrey Bidet   +10 more
wiley   +1 more source

Prevention and management of febrile neutropenia in acute myeloid leukaemia and higher risk myelodysplastic syndrome: An international survey of current practice

open access: yesBritish Journal of Haematology, EarlyView.
Summary Febrile neutropenia causes substantial morbidity in acute myeloid leukaemia and higher risk myelodysplastic syndrome. We aimed to describe current practice and priorities for clinical trials in the prevention and management of febrile neutropenia across Australia/New Zealand (ANZ), the United Kingdom (UK), Canada and Europe.
Aleece MacPhail   +14 more
wiley   +1 more source

Epigenetic mechanisms and therapeutic innovations in chronic pain‐associated neuropsychiatric co‐morbidities

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic pain, marked by nociceptive sensitization and maladaptive neuroplasticity, affects 30% of the global population with escalating socioeconomic burdens. Epidemiological data show a 2‐3‐fold increase in neuropsychiatric co‐morbidities among individuals with chronic pain, where epigenetic dysregulation serves as a key mechanism linking ...
Kai Zhang   +18 more
wiley   +1 more source

Erythema Nodosum Associated with Myelodysplastic Syndrome: A Case Report [PDF]

open access: yes, 2011
Adam, Christian   +3 more
core   +1 more source

Impact of Achieving Progression‐Free Survival 24 on Subsequent Overall Survival in Diffuse Large B‐Cell Lymphoma Patients

open access: yesCancer Science, EarlyView.
The OS for patients after achieving PFS24 or PFS60 was not markedly different from that of the age‐, sex‐, and calendar period‐matched Japanese general population (PFS24: standardized mortality ratio [SMR] 1.29, 95% confidence interval [CI] 0.72–2.12, p = 0.39; PFS60: SMR 1.43, 95% CI 0.47–3.33, p = 0.55).
Ayumi Fujimoto   +11 more
wiley   +1 more source

AllergoOncology in Review: Harnessing Allergy in the Field of Oncology to Improve Patient Outcomes

open access: yesClinical &Experimental Allergy, EarlyView.
ABSTRACT The AllergoOncology field brings together the study of allergic and cancer immune responses, having evolved from early epidemiological studies that reported inverse associations between allergies, IgE and cancer risk. Insights from studying allergic inflammation are revealing previously unappreciated immune mechanisms that confer protective ...
Jakub Zydron   +13 more
wiley   +1 more source

Clinical outcomes and safety in patients with lower‐risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial

open access: yes
British Journal of Haematology, EarlyView.
Rami S. Komrokji   +20 more
wiley   +1 more source

Factors Affecting Immune Reconstitution Post‐Allogeneic HSCT in Children: The Case for an Individualized Approach to Vaccination

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly used to treat malignant and non‐malignant diseases. Following allogeneic HSCT, patients are particularly vulnerable to vaccine‐preventable diseases (VPD) because conditioning depletes immune cells, including memory cells.
Hélène Buvelot   +3 more
wiley   +1 more source

Safety and effectiveness of the combination of 5‐azacitidine and ruxolitinib in VEXAS syndrome: A single‐centre experience

open access: yes
British Journal of Haematology, EarlyView.
Gregorio Maria Bergonzi   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy